BerGenBio ASA

Equities

BGBIO

NO0010650013

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.1504 ^NOK	-3.59%		-7.96%	-45.90%

Mar. 20	Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	CI
Feb. 14	BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

October 23, 2023 at 01:30 am EDT

BerGenBio ASA announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer (NSCLC) were presented during the European Society of Clinical Oncologists (ESMO) Annual Meeting 2023. In addition, on October 21st, Dr. Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in Bergen, Norway presented results of the Investigator Led Study LBA52 of bemcentinib in addition to pembrolizumab or the targeted therapies dabrafenib/trametinib in 1L and 2L metastatic melanoma patients.

Latest news about BerGenBio ASA

Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	Mar. 20	CI
BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
BerGenBio ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Transcript : BerGenBio ASA, Q4 2023 Earnings Call, Feb 14, 2024	Feb. 14
BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections	Feb. 07	CI
BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients	Dec. 15	CI
BerGenBio to End Bemcentinib Study in COVID-19 Trial Due to Lack of Patients	Dec. 15	MT
BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting	Dec. 11	CI
BerGenBio ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : BerGenBio ASA, Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Bergenbio Announces Data from Biomarker Analyses in 2L Nsclc	Nov. 06	CI
BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer	23-10-23	CI
Virax Biolabs Group Names Nigel McCracken Operating Chief.	23-09-01	MT
BerGenBio ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Transcript : BerGenBio ASA, Q2 2023 Earnings Call, Aug 23, 2023	23-08-23
BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-22	CI
BerGenBio ASA(OB:BGBIO) dropped from S&P Global BMI Index	23-06-19	CI
BerGenBio Drug Reduces Cancer Signs in Mid-stage Study	23-06-06	MT
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO	23-06-05	CI
Transcript : BerGenBio ASA - Special Call	23-06-02
BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors	23-05-22	CI
Transcript : BerGenBio ASA - Special Call	23-05-15
BerGenBio ASA Presents Data on STK11 Loss of Function and AXL Activation at AACR	23-04-18	CI
BerGenBio ASA Announces First Patient Dosed In Phase 1B/2A Trial Evaluating Bemcentinib In 1St Line Non-Small Cell Lung Cancer With Stk11 Mutations	23-03-09	CI
Transcript : BerGenBio ASA, Q4 2022 Earnings Call, Feb 16, 2023	23-02-16

Chart BerGenBio ASA

Duration

Period

More charts

Company Profile

Bergenbio ASA is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.1504 NOK

Average target price

0.7667 NOK

Spread / Average Target

+409.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BERGENBIO ASA	-45.90%	53.23M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs